Founded in 2015 and headquartered in St. Louis, Missouri, InterShunt focuses on developing catheter-based, minimally-invasive procedures to alleviate symptoms for millions suffering from heart failure. The company’s core mission is to provide effective heart failure relief through left atrial decompression without the need for implants. InterShunt aims to revolutionize heart failure treatment with its innovative, simple catheter procedure, targeting a significant unmet medical need in the cardiovascular market.
InterShunt has attracted notable scientific advisors and board members who are experts in cardiology and medical device innovation. The company has achieved significant milestones in clinical trials, demonstrating the efficacy and safety of its procedures. By offering a non-implant solution, InterShunt has the potential to significantly impact patient outcomes and reduce healthcare costs, positioning itself as a leader in the minimally-invasive heart failure treatment space.
